Explore the words cloud of the Hypo-RESOLVE project. It provides you a very rough idea of what is the project "Hypo-RESOLVE" about.
The following table provides information about the project.
STICHTING KATHOLIEKE UNIVERSITEIT
|Coordinator Country||Netherlands [NL]|
|Total cost||26˙774˙582 €|
|EC max contribution||13˙450˙057 € (50%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2018-05-01 to 2022-04-30|
Take a look of project's partnership.
|1||STICHTING KATHOLIEKE UNIVERSITEIT||NL (NIJMEGEN)||coordinator||2˙301˙983.00|
|2||THE UNIVERSITY OF SHEFFIELD||UK (SHEFFIELD)||participant||1˙990˙508.00|
|3||SYDDANSK UNIVERSITET||DK (ODENSE M)||participant||1˙354˙981.00|
|4||THE UNIVERSITY OF EDINBURGH||UK (EDINBURGH)||participant||1˙351˙453.00|
|5||REGION HOVEDSTADEN||DK (HILLEROD)||participant||1˙030˙750.00|
|6||UNIVERSITE DE LAUSANNE||CH (LAUSANNE)||participant||955˙601.00|
|7||SIB INSTITUT SUISSE DE BIOINFORMATIQUE||CH (GENEVE)||participant||934˙250.00|
|8||MEDIZINISCHE UNIVERSITAT GRAZ||AT (GRAZ)||participant||800˙000.00|
|9||THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE||UK (CAMBRIDGE)||participant||661˙202.00|
|10||EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH||DE (ST INGBERT)||participant||502˙125.00|
|11||CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER||FR (MONTPELLIER)||participant||465˙000.00|
|12||UNIVERSITA DEGLI STUDI DI PADOVA||IT (PADOVA)||participant||392˙687.00|
|13||UNIVERSITY OF DUNDEE||UK (DUNDEE)||participant||383˙622.00|
|14||KING'S COLLEGE LONDON||UK (LONDON)||participant||325˙891.00|
|15||ABBOTT DIABETES CARE||US (ALAMEDA)||participant||0.00|
|16||Eli Lilly and Company Limited||UK (Basingstoke)||participant||0.00|
|17||FEDERATION INTERNATIONALE DU DIABETE||BE (BRUXELLES)||participant||0.00|
|18||JDRF INTERNATIONAL||US (NEW YORK)||participant||0.00|
|19||MEDTRONIC INTERNATIONAL TRADING SARL||CH (TOLOCHENAZ)||participant||0.00|
|20||NOVO NORDISK A/S||DK (BAGSVAERD)||participant||0.00|
|21||SANOFI-AVENTIS DEUTSCHLAND GMBH||DE (FRANKFURT AM MAIN)||participant||0.00|
|22||THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST||US (NEW YORK)||participant||0.00|
|23||UNITIO INC||US (BOSTON)||participant||0.00|
Diabetes is one of the most prevalent global non-communicable diseases, affecting 60 million people in Europe, 10% of whom with type 1 diabetes. Normalising elevated glucose levels decreases symptoms, prevents microvascular complications, improves cardiovascular health and saves lives, but creates a significant risk for hypoglycaemia when insulin treatment is required. Hypoglycaemia is a serious event associated with cognitive decline, reduced quality of life, cardiovascular events and mortality. Hypoglycaemia remains the principal barrier to achieve glucose levels necessary to prevent diabetic complications of chronic hyperglycaemia. The overall objective of Hypo-RESOLVE is to alleviate the burden and consequences of hypoglycaemia, to be achieved by answering several key questions through a unique public-private partnership. Hypo-RESOLVE will construct secure sustainable databases with data from 100-150 clinical trials offering huge statistical power to establish the glucose threshold(s) below which hypoglycaemia constitutes a risk for poor outcomes in various populations. This will provide valuable input for an evidence based classification of hypoglycaemia to be adopted by regulators, patient organisations and other stakeholders, for application in future trials, the clinic and epidemiologic studies. The basic science and translational research line of Hypo-RESOLVE will advance our understanding on mechanisms underlying consequences of hypoglycaemia and explore novel pathways for the restoration of impaired awareness of hypoglycaemia. Finally, we will determine the significance of CGM-detected low glucose and investigate psychological and economic impacts of hypoglycaemia to quantify the burden of hypoglycaemia both for the individual and next-of-kin, as well as for society. Altogether, Hypo-RESOLVE will importantly further our knowledge of hypoglycaemia, (facilitate to) reduce its burden and contribute to a better life for patients with insulin-treated diabetes
|Updated review of the evidence surrounding our proposed classification||Documents, reports||2020-02-18 10:16:24|
|External Project Website||Websites, patent fillings, videos etc.||2020-02-18 10:16:25|
|Hypo-RESOLVE Position Paper||Documents, reports||2020-02-18 10:16:25|
Take a look to the deliverables list in detail: detailed list of Hypo-RESOLVE deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPO-RESOLVE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HYPO-RESOLVE" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.Read More
Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist DrugRead More